Stockscreener 앱 받기
4.88
3.84%
-0.195
Elicio Therapeutics Inc 주식(ELTX)의 최신 뉴스
Elicio Therapeutics Advances ELI-002 and Secures Funding - Yahoo Finance
Elicio reports promising cancer vaccine trial results By Investing.com - Investing.com Canada
Elicio Therapeutics Presents Updated Results from ELI-002 - GlobeNewswire
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO - The Bakersfield Californian
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 - Business Upturn
(ELTX) Investment Analysis and Advice - Stock Traders Daily
Elicio completes phase 2 enrollment for cancer vaccine By Investing.com - Investing.com Canada
Elicio completes phase 2 enrollment for cancer vaccine - Investing.com India
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment - GlobeNewswire
Elicio Therapeutics Completes Phase 2 Trial Enrollment for Pancreatic Cancer Treatment - StockTitan
SEC Form 424B3 filed by Elicio Therapeutics Inc. - Quantisnow
Elicio Therapeutics: Q3 Earnings Snapshot - mySA
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Elicio Therapeutics adjourns annual meeting due to lack of quorum - Investing.com
Elicio reports promising Phase 1 cancer vaccine trial results - Investing.com India
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting - GlobeNewswire
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study - The Bakersfield Californian
Elicio Therapeutics adjourns annual meeting due to lack of quorum By Investing.com - Investing.com UK
Jones Trading Initiates Coverage of Elicio Therapeutics (ELTX) with Buy Recommendation - MSN
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit - The Manila Times
Elicio Therapeutics to Present Clinical Data at the Society - GlobeNewswire
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy - Yahoo Finance
Elicio Therapeutics announces new CFO and accounting officer By Investing.com - Investing.com Australia
Elicio Therapeutics announces new CFO and accounting officer - Investing.com
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Reports Inducement Grants - GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted - The Bakersfield Californian
Elicio Therapeutics Announces Three Upcoming Presentations - GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - StockTitan
KalVista Appoints Brian Piekos as Chief Financial Officer - Business Wire
Elicio Therapeutics CFO resigns to pursue new opportunity By Investing.com - Investing.com Australia
Elicio Therapeutics CFO resigns to pursue new opportunity - Investing.com
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024 - InvestorPlace
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note - GlobeNewswire
Elicio Therapeutics’ US$40 Million ATM and US$11.5 Million Public Offering - Global Legal Chronicle
Therapeutic Vaccine Industry to Witness Massive Growth - openPR
ASCO 2024Chris Haqq - pharmaphorum
2.88%
2.65%
자본화:
|
볼륨(24시간):